SecBot SecBot
SECBOTREPLAY Home › Report › MLYS

MLYS · The FDA has accepted Mineralys Therapeutics' New Drug Application (NDA)…

Mineralys Therapeutics, Inc. · PRESS-RELEASE filed Mar 9, 2026 at 16:30 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 9, 2026 at 16:30 ET

The FDA has accepted Mineralys Therapeutics' New Drug Application (NDA) for lorundrostat, a treatment for adult hypertension, and set a PDUFA action date of December 22, 2026. While the Phase 2 Explore-OSA trial missed its primary endpoint of reducing apnea-hypopnea index in sleep apnea patients, it showed clinically meaningful blood pressure reduction and a favorable safety profile, supporting the drug's potential in resistant hypertension.

  • FDA accepted NDA for lorundrostat with PDUFA date of December 22, 2026
  • Lorundrostat demonstrated 6.2 mmHg placebo-adjusted systolic BP reduction in Explore-OSA trial (p < 0.0003)
  • Primary endpoint (AHI reduction) in Explore-OSA trial was not met
  • Drug showed favorable safety profile with no serum potassium excursions above 5.5 mmol/L

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access